Niacin

The Nutrition-Filled Beverage Is Rewriting the Script When It Comes to Energy Drinks FORT LAUDERDALE, Fla., March 12, 2024 /PRNewswire/ -- Traditional energy beverages have a negative reputation for unhealthy ingredients and sugary crashes. Bizz Energy was designed to be the ultimate zero-sugar energy drink. The healthy alternative to the classic concept was developed by a team led by entrepreneur Gavin Jacono. Part of the goal with Bizz Energy is to provide a potent dose of clean, sugar-free, crashless energy. However, Jacono and his team have gone above and beyond to ensure that the nutritional elements of their formula deliver more than a punchy pick-me-up. "Part of the point with Bizz Energy has always been to be a clean energy drink option," explains Jacono. "We want health-conscious individuals to be able to use it as a way to tap energy without compromising their health in the process. But our goal from day one was much bigger than that. We wanted a drink that could enhance performance on a nutritional level. We wanted something that brought together the ideas of an energy drink and a supplement." The first step in achieving this was to avoid classic sweet tooth ingredients, like sugar, high fructose corn syrup, and even aspartame. In addition, the group avoided any harmful chemicals or additives. When it came to the energy part of the process, the R&D team managed to create a unique form of soluble Turkesterone. The natural ecdysteroid has a reputation for stimulating physical and mental energy. This works alongside a punchy per-can dose of 200mg of caffeine anhydrous. Jacono's team also looked for ingredients that could provide a net nutritional positive to the consumer. They included ingredients like creatine and essential amino acids to help with muscle growth and protein synthesis. They also included Niacin and Biotin to support an active metabolism. In the end, the Bizz Energy formula is much more than an average energy drink — or even an improved one. It functions as a dual energy booster and supplement. It can supercharge the mind, energize the body, improve physical performance, and enhance whatever mental or physical activity an individual is attempting to accomplish. Bizz Energy is a refreshing new take on a classic concept. It is a clean, crashless, and nutritious energy drink built to help people reach their goals and go the distance. A bout Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Contact: Gavin Jacono 516-637-8701 374108@email4pr.com SOURCE Bizz Energy

Researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heart disease. Higher circulating levels of 4PY were strongly associated with development of heart attack, stroke and other adverse cardiac events in large-scale clinical studies. The researchers also showed in preclinical studies that 4PY directly triggers vascular inflammation which damages blood vessels and can lead to atherosclerosis over time. Cleveland Clinic researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team, led by Stanley Hazen, M.D., Ph.D., discovered a link between 4PY, a breakdown product from excess niacin, and heart disease. Higher circulating levels of 4PY were strongly associated with development of heart attack, stroke and other adverse cardiac events in large-scale clinical studies. The researchers also showed in preclinical studies that 4PY directly triggers vascular inflammation which damages blood vessels and can lead to atherosclerosis over time. The study, published in Nature Medicine, also details genetic links between 4PY and vascular inflammation. The findings provide a foundation for potential new interventions and therapeutics to reduce or prevent that inflammation. "What's exciting about these results is that this pathway appears to be a previously unrecognized yet significant contributor to the development of cardiovascular disease," said Dr. Hazen, Chair of Cardiovascular and Metabolic Sciences at Cleveland Clinic's Lerner Research Institute and Co-Section Head of Preventive Cardiology in the Heart, Vascular & Thoracic Institute. "What's more, we can measure it, meaning there is potential for diagnostic testing. These insights set the stage for developing new approaches to counteract the effects of this pathway." Niacin (vitamin B-3) is very common in a Western diet. "For decades, the United States and more than 50 nations have mandated niacin fortification in staple foods such as flour, cereals and oats to prevent disease related to nutritional deficiency," said Dr. Hazen. Yet one in four subjects in the researchers' patient cohorts appear to be getting too much, and had high levels of 4PY, which appears to contribute to cardiovascular disease development. Dr. Hazen compares our intake of niacin as multiple taps pouring water into a bucket. Once that bucket is filled, it begins to spill over. The human body then needs to process that spill-over and produce other metabolites, including 4PY. "The main takeaway is not that we should cut out our entire intake of niacin -- that's not a realistic approach," said Dr. Hazen. "Given these findings, a discussion over whether a continued mandate of flour and cereal fortification with niacin in the U.S. could be warranted." Dr. Hazen notes broader use of over-the-counter supplements made with different forms of niacin have also become popular because of presumed anti-aging purposes. He adds that patients should consult with their doctors before taking over-the-counter supplements and focus on a diet rich in fruit and vegetables while avoiding excess carbohydrates. The new findings also might help explain why niacin is no longer a go-to treatment for lowering cholesterol. Niacin was one of the first treatments prescribed to lower LDL or "bad" cholesterol. However, eventually niacin showed to be less effective than other cholesterol-lowering drugs and was associated with other negative effects and higher mortality rates in previous research. "Niacin's effects have always been somewhat of a paradox," Dr. Hazen said. "Despite niacin lowering of cholesterol, the clinical benefits have always been less than anticipated based on the degree of LDL reduction. This led to the idea that excess niacin caused unclear adverse effects that partially counteracted the benefits of LDL lowering. We believe our findings help explain this paradox. This illustrates why investigating residual cardiovascular risk is so critical; we learn so much more than what we set out to find." The study authors note that long-term investigations are needed to assess the effect of chronic elevation of 4PY levels on atherosclerosis and other phenotypes. The research is part of Dr. Hazen's ongoing investigation into factors that contribute to residual cardiovascular risk. His team follows patients over time and collects blood samples to find chemical signatures that can predict the development of heart disease. He has made pioneering discoveries in atherosclerosis and inflammatory disease research, including the seminal discovery linking gut microbial pathways to cardiovascular disease and metabolic diseases. Dr. Hazen also directs Cleveland Clinic's Center for Microbiome and Human Health and holds the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis. Marc Ferrell, a former M.D., Ph.D. student in Dr. Hazen's laboratory and student in Case Western Reserve University's Medical Scientist Training Program, is first author of the manuscript. Research reported in this publication was supported in part by the National Institutes of Health under award numbers R01HL103866, P01HL147823, R01HL133169, R01HL148110, R01HL168493, and U54HL170326.